Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings

LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
January 27, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited- PDMR Dealing

LONDON and BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
January 26, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited - Interim results for the six months to 30 September 2021

LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO) a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye...
December 14, 2021 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma announces issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease

LONDON and BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
December 13, 2021 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
December 06, 2021 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis

LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory...
December 01, 2021 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited: Directorate Change

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with...
September 27, 2021 07:17 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting

LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye...
September 09, 2021 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting

LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
August 02, 2021 06:57 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during...